WAYNE, Pa. — November 4, 2025 — Leads & Copy — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will report its third quarter 2025 financial results before the market opens on Tuesday, November 11, 2025. Management will host a conference call for investors at 8:30 a.m. ET to discuss the results and provide a corporate update.
To access the live webcast of the call with slides, click here or visit the “Events & Presentations” section of Palvella’s website. To access the call by phone, use this registration link for dial-in details. A replay will be available approximately 2 hours after the call and archived for 90 days on the company’s website.
Palvella Therapeutics, founded by rare disease drug development veterans, focuses on developing and commercializing novel therapies for serious, rare skin diseases without FDA-approved therapies. The company is developing a pipeline based on its patented QTORIN™ platform, initially targeting severe, rare genetic skin diseases. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is being evaluated in Phase 3 and Phase 2 clinical trials for various conditions.
QTORIN™ rapamycin is for investigational use only and has not been approved by the FDA or any regulatory agency for any indication.
Contact Information
Investors:Wesley H. Kaupinen, Founder and CEO, Palvella Therapeutics, wes.kaupinen@palvellatx.com
Media:Marcy Nanus, Managing Partner, Trilon Advisors, LLC, mnanus@trilonadvisors.com
Source: Source: Palvella Therapeutics
